Ontology highlight
ABSTRACT: Importance
New therapeutic classes of migraine-specific treatment have been developed, including 5-hydroxytryptamine1F receptor agonists (lasmiditan) and calcitonin gene-related peptide antagonists (rimegepant and ubrogepant).Objective
To compare outcomes associated with the use of lasmiditan, rimegepant, and ubrogepant vs triptans for acute management of migraine headaches.Data sources
The Cochrane Register of Controlled Trials, Embase, and PubMed were searched from inception to March 5, 2020.Study selection
Double-blind randomized clinical trials examining current available migraine-specific acute treatments were included.Data extraction and synthesis
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was appl
SUBMITTER: Yang CP
PROVIDER: S-EPMC8506232 | biostudies-literature | 2021 Oct
REPOSITORIES: biostudies-literature